Cancer-Associated Intermediate Conductance Ca2+-Activated K+ Channel KCa3.1
AbstractSeveral tumor entities have been reported to overexpress KCa3.1 potassium channels due to epigenetic, transcriptional, or post-translational modifications. By modulating membrane potential, cell volume, or Ca2+ signaling, KCa3.1 has been proposed to exert pivotal oncogenic functions in tumorigenesis, malignant progression, metastasis, and therapy resistance. Moreover, KCa3.1 is expressed by tumor-promoting stroma cells such as fibroblasts and the tumor vasculature suggesting a role of KCa3.1 in the adaptation of the tumor microenvironment. Combined, this features KCa3.1 as a candidate target for innovative anti-cancer therapy. However, immune cells also express KCa3.1 thereby contributing to T cell activation. Thus, any strategy targeting KCa3.1 in anti-cancer therapy may also modulate anti-tumor immune activity and/or immunosuppression. The present review article highlights the potential of KCa3.1 as an anti-tumor target providing an overview of the current knowledge on its function in tumor pathogenesis with emphasis on vasculo- and angiogenesis as well as anti-cancer immune responses. View Full-Text
Share & Cite This Article
Mohr, C.J.; Steudel, F.A.; Gross, D.; Ruth, P.; Lo, W.-Y.; Hoppe, R.; Schroth, W.; Brauch, H.; Huber, S.M.; Lukowski, R. Cancer-Associated Intermediate Conductance Ca2+-Activated K+ Channel KCa3.1. Cancers 2019, 11, 109.
Mohr CJ, Steudel FA, Gross D, Ruth P, Lo W-Y, Hoppe R, Schroth W, Brauch H, Huber SM, Lukowski R. Cancer-Associated Intermediate Conductance Ca2+-Activated K+ Channel KCa3.1. Cancers. 2019; 11(1):109.Chicago/Turabian Style
Mohr, Corinna J.; Steudel, Friederike A.; Gross, Dominic; Ruth, Peter; Lo, Wing-Yee; Hoppe, Reiner; Schroth, Werner; Brauch, Hiltrud; Huber, Stephan M.; Lukowski, Robert. 2019. "Cancer-Associated Intermediate Conductance Ca2+-Activated K+ Channel KCa3.1." Cancers 11, no. 1: 109.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.